Resources

There are currently significant discrepancies between Canadian provinces and territories in the criteria for access to advanced targeted agents for rheumatoid arthritis (RA) treatment. Such targeted agents include biologic medications as well as small molecule inhibitors. In hopes of supporting […]

This new position statement replaces the Canadian Rheumatology Association Position Statement on COVID-19 Vaccination (latest update published March 2022), and advocates for government coverage for vaccines not currently funded for rheumatology patients.

The antimalarial drugs, hydroxychloroquine (HCQ) and rarely chloroquine, are essential drugs in the treatment of rheumatic diseases. HCQ is currently the only anti-malarial drug available in Canada for the treatment of rheumatic diseases...

The Canadian Rheumatology Association (CRA) strongly opposes Bill 2, recently enacted by the Government of Quebec. This legislation introduces coercive measures that undermine physicians’ rights, destabilize the health care system, and threaten the quality of care for patients living with […]

JAK inhibitors (JAKi) are an effective treatment for several rheumatic conditions, including rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS) and juvenile idiopathic arthritis (JIA)...

The antimalarial drugs, chloroquine and especially hydroxychloroquine (HCQ), are essential drugs in the treatment of rheumatic diseases...

Biologic medications have become a cornerstone of the treatment for rheumatic diseases in adults and children in Canada. As more biologic options become available, including biosimilars, the ability of patients to access different biologic agents or switch between different formulations […]

Patients with autoimmune diseases such as systemic sclerosis (scleroderma) often have severe Raynaud’s phenomenon (RP) which may or may not be associated with digital ulcers. There are other diseases that may have severe RP as a manifestation such as but […]

Drug shortages and limited medication access due to cost have direct impacts on effective pharmacologic management of rheumatic diseases...

A sustainable rheumatology workforce is essential to achieve the mission of the Canadian Rheumatology Association (CRA), Most importantly, a sustainable rheumatology workforce is necessary to meet Canada’s population health needs, and to address the priorities of better access, better health, […]

While most Canadians hold the perception that arthritis only affects adults and the elderly, a range of rheumatic and musculoskeletal diseases (RMD) affect youth...

Virtual care is an emerging term adopted by the Canadian Medical Association (CMA) as “any interaction between patients and/or members of their circle of care, occurring remotely, using any forms of communication or information technologies with the aim of facilitating […]